Structure-Based Drug Design Strategy

Overview

Structure-based drug design (SBDD) uses 3D structural information about a biological target — typically a protein — to reason about how small molecules or fragments can bind and modulate its function. This skill encodes methodology for the decisions that dominate SBDD outcomes: whether the target is druggable, which computational method fits the question, how to define and validate a binding site, how to interpret poses and scores, and when to escalate from docking to molecular dynamics (MD) or free energy perturbation (FEP). It does not generate code or run tools; it guides strategy, critique, and experimental planning.

The central claim of SBDD is that structure constrains chemistry. A well-chosen method applied to a well-prepared structure with a correctly defined site yields actionable hypotheses. The same method applied without that care produces plausible-looking poses and scores that do not translate to activity. Most failure modes in SBDD are strategic, not technical.

Usage

Load this skill when the user is planning or critiquing structure-based design decisions. Typical entry points:

• "Is this target druggable?" — use Druggability Assessment.
• "Should I use rigid or flexible docking?" — use Docking Strategy Selection.
• "My docking scores don't correlate with activity." — use Interpreting Docking Results and Common Mistakes.
• "How do I rank this congeneric series?" — use When to Escalate Beyond Docking (FEP).
• "I have a cryptic or allosteric site." — use Binding Site Definition and consider MD.
• "Design a virtual screening campaign." — use Virtual Screening Cascade.
• "Fragments vs HTS?" — use Fragment vs HTS Screening.